Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Polycystic ovary syndrome and offspring risk of congenital heart defects: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A rare missense variant in APC interrupts splicing and causes AFAP in two Danish families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Mads Thomassen
  • Ana Blanco
  • Marco Montagna
  • Thomas V O Hansen
  • Inge Søkilde Pedersen
  • Sara Gutiérrez-Enríquez
  • Mireia Menéndez
  • Laura Fachal
  • Marta Santamariña
  • Ane Y Steffensen
  • Lars Jønson
  • Simona Agata
  • Phillip Whiley
  • Silvia Tognazzo
  • Eva Tornero
  • Uffe Birk Jensen
  • Judith Balmaña
  • Torben A Kruse
  • David E Goldgar
  • Conxi Lázaro
  • Orland Diez
  • Amanda B Spurdle
  • Ana Vega
Vis graf over relationer
Mutations in BRCA1 and BRCA2 predispose carriers to early onset breast and ovarian cancer. A common problem in clinical genetic testing is interpretation of variants with unknown clinical significance. The Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium was initiated to evaluate and implement strategies to characterize the clinical significance of BRCA1 and BRCA2 variants. As an initial project of the ENIGMA Splicing Working Group, we report splicing and multifactorial likelihood analysis of 25 BRCA1 and BRCA2 variants from seven different laboratories. Splicing analysis was performed by reverse transcriptase PCR or mini gene assay, and sequencing to identify aberrant transcripts. The findings were compared to bioinformatic predictions using four programs. The posterior probability of pathogenicity was estimated using multifactorial likelihood analysis, including co-occurrence with a deleterious mutation, segregation and/or report of family history. Abnormal splicing patterns expected to lead to a non-functional protein were observed for 7 variants (BRCA1 c.441+2T>A, c.4184_4185+2del, c.4357+1G>A, c.4987-2A>G, c.5074G>C, BRCA2 c.316+5G>A, and c.8754+3G>C). Combined interpretation of splicing and multifactorial analysis classified an initiation codon variant (BRCA2 c.3G>A) as likely pathogenic, uncertain clinical significance for 7 variants, and indicated low clinical significance or unlikely pathogenicity for another 10 variants. Bioinformatic tools predicted disruption of consensus donor or acceptor sites with high sensitivity, but cryptic site usage was predicted with low specificity, supporting the value of RNA-based assays. The findings also provide further evidence that clinical RNA-based assays should be extended from analysis of invariant dinucleotides to routinely include all variants located within the donor and acceptor consensus splicing sites. Importantly, this study demonstrates the added value of collaboration between laboratories, and across disciplines, to collate and interpret information from clinical testing laboratories to consolidate patient management.
OriginalsprogEngelsk
TidsskriftBreast Cancer Research and Treatment
Vol/bind132
Udgave nummer3
Sider (fra-til)1009-23
Antal sider15
ISSN0167-6806
DOI
StatusUdgivet - 2012

ID: 36600829